This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation
Chinese Journal of Cancer Open Access 19 May 2016
-
New drug approvals in acute myeloid leukemia: what’s the best end point?
Leukemia Open Access 18 December 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gale, R. Measureable residual disease (MRD): much ado about nothing?. Bone Marrow Transplant 50, 163–164 (2015). https://doi.org/10.1038/bmt.2014.239
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2014.239
This article is cited by
-
Measurable residual disease testing in acute myeloid leukaemia
Leukemia (2017)
-
Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation
Chinese Journal of Cancer (2016)
-
New drug approvals in acute myeloid leukemia: what’s the best end point?
Leukemia (2016)